UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

#### 144: Filer Information

Filer CIK 0001802897 Filer CCC XXXXXXXX Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name

Phone

E-Mail Address

#### 144: Issuer Information

Name of Issuer BioNTech SE 001-39081 SEC File Number

An der Goldgrube 12

Mainz Address of Issuer **GERMANY** 

55131

Phone 49613190840

Name of Person for Whose Account the Securities are To Be Sold ATHOS KG

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

10% Stockholder Relationship to Issuer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares representing ordinary shares, no par value per share	J.P. Morgan Securities LLC 390 Madison Avenue - 6th Floor New York NY 10017	75000	8484750	237725735	11/25/2024	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	<b>Payment</b>	Payment *

	Transaction	Whom Acquired	a Acquired Gift?	<b>Acquired</b>	
Ordinary Shares, no par value per share	01/05/2018 Private placement	BioNTech SE		75000	01/05/2018 Cash

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	<b>Gross Proceeds</b>
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/13/2024	170000	19552584
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/16/2024 :	590000	72893611
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/17/2024	30162	3754792
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/18/2024 :	55605	6934500
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/25/2024	37943	4495107
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/27/2024	37204	4376679
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/30/2024	76114	8998197
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/01/2024	72086	8595657
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/02/2024	65200	7761193
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/03/2024	50000	5963585
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/04/2024	14756	1812078
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/07/2024	20295	2488325
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/08/2024	15000	1830101
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/09/2024	6000	714360

AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/10/2024 20000	2349436
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/11/2024 40000	4805228
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/14/2024 25424	3071964
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	10/16/2024 8036	946154

## 144: Remarks and Signature

The filing of this Form 144 shall not be construed as an admission that the undersigned is an affiliate of the issuer.

All ADS to be sold by AT Impf GmbH.

Date of Notice

Remarks

11/25/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for /s/ Thomas Maier /s/ Stephan Sperber

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)